The importance of multicolor flow cytometry for immunophenotyping and immunomonitoring is ever increasing in multiple applications. Today, research and clinical laboratories addressing various immunologic aspects rely heavily on flow cytometry for phenotypic and functional analyses of immune components in different disease settings and in the healthy immune system. Flow cytometry currently is the only technology platform that suitably can analyze the complex components of the immune system (ie, separately characterize the dozens, or hundreds, of phenotypically and functionally distinct subsets of leukocytes, any of which might be clinically relevant). Multicolor flow cytometry assays, therefore, need to be developed with care in order to ensure reliability of data generated therewith. This article illustrates the process of generating and optimizing a complex immunophenotyping panel to address vaccine-induced T-cell responses.
The importance of multicolor flow cytometry for immunophenotyping and immunomonitoring is ever increasing in multiple applications. Today, research and clinical laboratories addressing various immunologic aspects rely heavily on flow cytometry for phenotypic and functional analyses of immune components in different disease settings and in the healthy immune system. Flow cytometry currently is the only technology platform that suitably can analyze the complex components of the immune system (ie, separately characterize the dozens, or hundreds, of phenotypically and functionally distinct subsets of leukocytes, any of which might be clinically relevant). Multicolor flow cytometry assays, therefore, need to be developed with care in order to ensure reliability of data generated therewith. This article illustrates the process of generating and optimizing a complex immunophenotyping panel to address vaccine-induced T-cell responses.
With the advent of instrumentation capable of measuring up to 20 parameters, new possibilities for performing more complete and more complex analyses have opened up. This has spurred the search for correlates of protection and correlates of disease [1] , which are necessary for the rapid evaluation of immunologic interventions. In addition, there is the possibility of identifying phenotypically unique cellular subsets to which distinct functional responses can be attributed; such assignments possibly preclude, or at least reduce, the necessity of performing time-consuming functional assays for the evaluation of antigen-specific immune responses. This is based on the presumption that cells with a given phenotype are an indication of a productive immune response in a given disease setting, whereas other phenotypes are indicative of inefficient responses or even of cellular activity leading to pathologies. The relationship between phenotype and desirability of the response may vary considerably in different disease contexts and tissue environments.
The complexity of the T-cell compartment, phenotypically and functionally, is enormous. Unfortunately, virtually none of the T-cell subsets can be uniquely identified by the expression of one or even a few molecules, and, generally, the simultaneous discrimination of the expression patterns of four or more molecules is required [2] . Thus, the advent of polychromatic flow cytometry (measuring five or more colors) has had a dramatic impact on the ability to reveal T-cell biology.
The complexity in the design, implementation, and analysis of such experiments increases geometrically, however, with the number of colors used; there is a wide range of hurdles and problems that must be addressed. This article describes some of the common ones and lays out a general plan for succeeding with multicolor experiments.
Considerations in choosing a flow cytometer
Most newer machines used in research and diagnostics today typically measure 6 to 12 parameters. Although this article focuses on the development of a 15-color (17-parameter) panel, the process described applies to all polychromatic assays, whether 4 or 18 colors are being measured. Meticulous development of an antibody panel always proves rewarding in the end.
Today's most sophisticated flow cytometers can measure 20 parameters simultaneouslydtwo physical parameters (cell size and granularity) and 18 fluorescences (Table 1) . If polychromatic flow cytometry is used (eg, for immunophenotyping during vaccine studies), the authors recommend acquiring such a high-end machine. Even though the possibility exists, the aim is not to develop 18-color panels for all scientific questions. More importantly, the more fluorescence detectors an instrument incorporates, the more flexibility it provides to researchers with respect to assay development, because detector numbers do not become a constraint. This increases the likelihood of being able to accommodate antibodies to all antigens desired to be evaluated in a particular assay, by giving the option of choosing from more antibody conjugates. Table 1 illustrates the configuration of LSR II flow cytometers used in the authors' laboratory. Because all fluorochromes excited by the green laser (532 nm excitation)dwith the exception of Ax594dalso can be measured off the blue laser (488 nm excitation), it is not absolutely necessary to install four lasers in this instrument. The green laser increases immunofluorescence sensitivity, however, in comparison to the blue laser [3] and provides for the detection of an additional unique color.
Initial considerations
As increasing numbers of parameters are evaluated in single samples, the importance of adhering to a meticulous optimization strategy cannot be overemphasized [4] . Design and analysis of multicolor assays become more complex and time consuming as more parameters are included. To illustrate the process of designing and optimizing such an assay, the steps undertaken for the development of a panel to be used to evaluate CD4 þ and CD8
þ T-cell responses in human peripheral blood mononuclear cell The latter reportedly are the most stable, allowing their use in combination with intracellular flow cytometry, which requires fixation and permeabilization of cells [5] . Additionally, they outrank PI and annexin V in identifying the highest proportion of dead cells [5] .
Flow cytometry enjoys widespread use in research and diagnostics, thanks in part to the growing number of fluorescent reagents that are available. Although some of the more classical dyes used to label antibodies, such as phycoerythrin (PE), have broad emission spectra, some of the newer reagents have narrower emission spectra. This is important, for it minimizes spillover into other fluorescence detectorsda process that reduces sensitivity for measuring the desired fluorescence in those detectors. The recently introduced semiconductor nanocrystals, known as quantum dots (Q-dots), offer several distinct fluorescent particles excited by the violet laser [6] . Q-dot reagents do not work well for all antibodies, however, and are difficult to optimize for the detection of intracellular molecules. With all fluorochromes, but especially with Q-dots, unbound particles potentially can interact with each other, forming aggregates. Such aggregates need to be minimized by subjecting the antibody dilutions to a quick high-speed spin, as they label some cells nonspecifically.
Sensitivity is a serious issue when developing multicolor panels. The sensitivity of a reagent is determined by three factors: the cell's autofluorescence in that region of the spectrum, the performance of the antibody conjugate (brightness of the fluorochrome and expression level of the molecule), and the presence of other antibody conjugates attached to the same cell (that result in spillover fluorescence into the same detector). Not all fluorochromes provide the same sensitivity because of substantial differences in brightness. Furthermore, including more reagents typically decreases the sensitivity of a given antibody conjugate because of the accumulated interference from spillover fluorescences.
To maintain the highest possible sensitivity for all antigens to be analyzed, the best reagent panel has to be identified by an iterative process of testing antibody conjugates and putative panels. At each stage, the performance of the panel is compared with the previous step, so as to know which interactions are causing any loss in sensitivity, thereby providing an indication as to whether or not the panel requires adjustment.
The grid
Initially, a list of antigens of interest is drawn upda ''wish list'' of antigens to be included in the analysis. It is useful to include a ranking of importance in case not all of them are able to be included in the final panel. The antigens subsequently are assigned to one of the following three categories:
1. Primary antigensdthose that are well characterized and identify broad subsets of cells. Their expression usually is ''on'' or ''off'' and used to gate on cellular subsets of interest (eg, CD3, CD4, CD8, CD14, CD19, or CD20). 2. Secondary antigensdthese are well characterized with relatively high molecular density per cell. Their expression pattern, however, often is a continuum (eg, CD27, CD28, CD45RA/RO, IFN-g, or perforin). 3. Tertiary antigensdthese are expressed at low levels only (eg, CD25 or chemokine receptors). Uncharacterized antigens also fall into this category.
To be able to select the best antibody conjugate for every antigen of interest, multiple reagents need to be tested for each antigen. The authors' approach is to purchase many reagents for primary, fewer for secondary, and only one or two (with the brightest fluorochromes [eg, PE or allophycocyanin (APC)]) for tertiary antigens. This is expensive, but the investment is worth it, as it allows the development of the ideal reagent panel for the research question at hand. Panels often are developed for the subsequent analysis of a large number of samples, so the total expenditure for antibodies always is large. The gain from having a highly optimized panel offsets the information cost from testing only a limited number of initial conjugates; do not skimp on the testing and optimization phase! Before proceeding, all antibodies need to be titrated carefully and the optimal titer recorded. All antibody conjugatesdincluding disparate antibody clones and different dyes read in single detectorsdavailable for the antigens of interest then are screened systematically in single-color experiments. For those antigens known to be expressed on small subsets of cells only, samples are stained specifically for those subsets in order to facilitate subsequent analysis of the antibody screening results. After carefully gating on single lymphocytes, dot plots are created to compare the performance of the various reagents. Results are grouped by detectors and dyes and the best antibody conjugate chosen for each detector and antigen then is inserted into a grid (Fig. 1) . Such a grid, where dot plots are sorted by antigen versus detector, is extremely useful for subsequently selecting possible antibody combinations to be tested in potential multicolor panels.
In the process of allocating candidate detectors for the different antigens, those antigens where only few antibody conjugates are available or those where good labeling is not obtained easily are considered first. Generally, bright fluorochromes, such as PE and APC, preferentially are chosen for weak antigens, where only low numbers of molecules are expressed per cell or for those that are expressed by only a small fraction of cells (tertiary antigens). Starting with the most difficult antigen (few antibody conjugate options or expressed on a small subpopulation of T cells only), in this example CD107a, the options are compared and the optimal staining identified Fig. 1 . The antigen/detector grid. The indicated antigens are read on the Y axis. For CCR7 and CD27, CD45RA expression was coanalyzed (X axis), whereas for CD45RA, CCR7 was co-analyzed. For CD107a, CD4 expression is shown on the X axis, whereas for CD154, IFN-g, IL-2, macrophage inflammatory protein [MIP]-1b, and TNF-a, CD8 is illustrated on the X axis. Orange frames highlight those antibodies included in the antibody panel to be tested, whereas green frames mark the detectors that are not used in the panel and potentially could be exploited to include further markers in the assay. Blue frames indicate those antigens not included in the selected antibody panel. Numbers on the right side of the table indicate primary (1 ), secondary (2 ), and tertiary (3 ) antigens.
and marked. After assigning a fluorochrome for CD107a, the corresponding detector is blocked for all other antigens, a process which is easily visualized using the grid. This process is repeated for all tertiary antigens, then all secondary antigens, until finishing with primary antigens, such as CD3, CD4, and CD8, that are expressed by relatively large proportions of cells and at a high molecular density and where, typically, a large selection of antibody conjugates are available. Ideally, several different panels (perhaps half a dozen or more) evaluating different combinations of these reagents are tested in the first rounds.
Evaluating candidate antibody panels
To evaluate which, if any, of the selected putative antibody panels will provide reliable staining of all antigens of interest, cells are incubated not only with the full sets of antibodies making up a panel but also with subsets thereof. This permits the identification of those antibody conjugates that create problems of interference (ie, reduced sensitivity). Ideally, a basic roster of antibodies is identified first, which marks major subsets, such as CD4 þ and CD8 þ T cells. In subsequent samples, the remaining antibodies are added one at a time, in order to evaluate the effect of each added reagent to the overall staining pattern. During this process, it makes sense to add antibodies in the sequential order that will be required for gating purposes during the analysis. Alternate antibody conjugates can be tested rapidly in this manner, leading to the gradual build-up of the final antibody panel.
In the example illustrated in Fig. 2 , antibody conjugates are added one at a time, and dot plots created accordingly to depict the labeling achieved with the respective reagent and any putative effect on other reagents included in the sample. Fig. 3A illustrates a decrease in sensitivity for the dead cell marker, ViViD, on addition of CD28 . As in the example, ViViD was added at the same time as the antibody conjugates; there are two possible explanations for this phenomenon: (1) it might indicate that there is something in the CD28 PE-Cy5 antibody preparation (eg, amines or free protein) that interferes with the ViViD reaction or (2) the fact that this antibody conjugate was used at a relatively high concentration (25 mL in100 mL) was sufficient to dilute the ViViD enough to reduce its staining intensity. A solution to this is to perform separate incubations for the ViViD and antibody conjugates specific for surface markers.
These plots also indicate that the CD3-labeling was not successful or at least not bright enough to allow distinction of CD3 þ and CD3 À cells. This was because of the CytoStim (anti-CD3 and anti-CD28 antibody preparation from BD Biosciences) stimulation providing strong activatory stimuli to all T cells, resulting in severe down-regulation of the CD3 molecule. Parallel labeling of an unstimulated PBMC sample with the same antibody mixture shows that the antibody conjugate does perform well (Fig. 3B) . The patient samples the authors are interested in ultimately will be stimulated with peptide before flow cytometric analysis, and it is expected that peptide stimulation does not induce such an extreme CD3 down-regulation, although this will have to be verified before commencing the study. This illustrates an important aspect of panel development: at all phases, putative panels must be tested in exactly the Fig. 2 . Progressive construction of a multicolor analysis panel. To determine whether or not antibody conjugates selected for a multicolor panel produce signal interference, a series of samples was labeled with subsets of the antibodies making up the panel. The first sample contained one antibody conjugate only (plus ViViD to exclude dead cells), whereas each subsequent sample contained one more antibody conjugate. Each row depicts plots from a single sample, and the antibody conjugate added at each point is indicated at the left of each respective row. For each sample, dot plots were created that follow the gating strategy to be used during analysis as far as it can be predicted. This allows the identification of antibody conjugates that create signal interferences with other antibody conjugates or simply do not result in sufficient detection sensitivity in the present antibody combination.
conditions of the final assay; there are aspects of experimental procedures that may have an impact on sensitivity that are not revealed simply by labeling untreated fresh cells.
An apparent loss of sensitivity in the CD28 detection is illustrated in Fig. 3C , which depicts CD127 (X-axis) against CD28 (Y-axis) expression on CD4 pos CD27 neg CD45RA neg T cells before and after addition of an IFN-g APC conjugate. In the upper panel (no IFN-g APC ), CD28 pos and CD28 neg cells clearly are separated, whereas in the lower panel (IFN-g APC added), the negative population seems to be scattered toward the positive population, hampering unambiguous distinction of these two cellular fractions. A pseudocolor plot illustrating CD28 versus IFN-g expression revealed that, in this case, APC was not compensated sufficiently, resulting in significant spillover into other detectors, most notably into the G660, which is dedicated to measuring CD28 PE-Cy5 in the present panel. The problem was that the APC fluorescence achieved by labeling the compensation control beads (CompBeads) with IFN-g APC was less bright than that obtained in the PBMC samples. Therefore, the software was not able to compensate the signals properly, as it did not have any information on the behavior of signals brighter than those in the compensation control sample. This spillover could be corrected by adjusting the compensation matrix. Once corrected, the CD28 separation was improved significantly, although there still was loss of sensitivity brought about by the inclusion of IFN-g APC in the panel. This loss is the result of the spillover-induced spreading of the negative population in the G660 detector (specific for PE-Cy5) (for a full explanation of this phenomenon, see Roederer [7] ). The long-term solution for this specific issue is to include a cell-based compensation control for this detector, ensuring that the compensation control is at least as bright as the experimental sample. For other detectors, the bead-based compensation controls were sufficiently bright and resulted in appropriate compensation calculations. Fig. 3D highlights that there was weak IL-2 detection and only limited detection of CD154 expression, even though the CD154 specific antibody conjugate was added to the stimulation culture, which is the best labeling strategy for detection of this molecule on activated CD4 þ T cells [8] . It is expected that a larger fraction of CD4 þ cells would produce IL-2 and at a higher level than indicated by the present labeling. Other CD154 and IL-2 specific antibody conjugates will have to be evaluated in the context of this antibody panel in order to identify better combinations.
Lastly, the experiment did not allow any conclusion as to whether or not the reagents chosen for programmed death 1 (PD-1) detection provide adequate detection sensitivity in conjunction with the other reagents included in the panel (Fig. 3E) . The reason for this is that PD-1 typically is expressed at low levels on T cells from healthy individuals, its expression being up-regulated on memory CD8 þ T cells specific for poorly controlled, chronically persistent viruses, such as HIV [9] . The panel, therefore, would need to be re-evaluated on PBMC from an HIV-infected individual or on cells that were stimulated for several days.
''Spreading errors'' (a consequence of imprecise measurement and compensation) [7] can differ highly between fluorochrome-antigen pairs. Labeling antigens, such as CD3, CD4, CD8, and CD45, which are highly expressed on lymphocytes, often results in bright signal intensities. A QD655-labeled anti-CD4 antibody (measured by the V655 detector) (see Table 1 ) demonstrates significant spreading error in the G660 detector and, to a lesser extent, in the R660 detector, even after the mean fluorescence intensities of CD4 neg and CD4 pos cells have been aligned correctly (Fig. 4A) . This is because all three detectors (V655, G660, and R660) measure similar wavelengths (640 nm to 680 nm). The G660 detector is affected more severely, however, by very bright signals that should be measured in the V655 detector than the R660 detector. As a consequence, the minimal fluorescence intensity of PE-Cy5-signals (on the G660 detector) detectable on CD4 neg and CD4 pos cells are very different (Fig. 4B ) [3, 10] . This also holds true for other antibody and fluorochrome combinations, respectively. It is advisable, therefore, to monitor spreading errors closely in other detectors and, where possible, to prevent this effect by changing the antibody combination (see Fig. 4B ). In the example, reducing the anti-CD4 QD655 antibody titer by one tenth eliminated . Diluting the reagent by one tenth obliterates this problem. (B) Spreading error of QD655 þ cells reduces the sensitivity of the G660 detector for PE-Cy5 þ signals on QD655 À cells (red lines). The severe spreading error observed with previously titrated amounts of anti-CD4 QD655 (V655) in the G660 detector can be ameliorated either be using a lower titer of the anti-CD4 QD655 antibody or by replacing it with another anti-CD4 conjugate, such as an anti-CD4 APC antibody (R660).
the dramatic spreading error in the G660 detector while still providing a good separation between CD4 neg and CD4 pos cells.
Sample preparation
The number of cells per sample depends much on the scientific question addressed (eg, whether or not one is interested in analyzing total T cells or only a subset of T cells). The total number of cells acquired needs to be estimated to include sufficient events for the cell population of interest in order to provide clearly definable subpopulations and results that can be evaluated statistically.
Most antibodies bind well at room temperature or 4 C, the two incubation temperatures used most commonly for flow cytometry assays. In the authors' laboratory, cells routinely are labeled at room temperature. In some cases, however, incubation at higher (37 C) temperatures is found to increase an antibody's binding to its antigen. Chemokines and chemokine receptors are found to be exceptionally sensitive to variations in cell isolation and staining techniques [11] . The optimal protocol for most, but not all, of these molecules is found to be lymphocyte enrichment over a Ficoll-gradient followed by labeling at 37 C. A good example of one such chemokine receptor is CCR5. Conversely, other antigens, such as CXCR6, do not tolerate incubations at 37 C well, resulting in severely reduced or even abrogated detection [11] .
In panels incorporating antibodies to extracellular and intracellular proteins, a sequential labeling protocol needs to be applied. If a dead cell marker dye, such as an amine-reactive dye, is to be included, the authors suggest first incubating the samples with the dead cell marker dye before proceeding with cell surface marker labeling, fixation/permeabilization, and finally labeling of intracellular markers. Not all dead cell marker dyes are compatible with the fixation/permeabilization process required for intracellular labeling [12] . Similarly, some tandem dyes are not completely spectroscopically stable to the fixation/permeabilization procedure required for the labeling of intracellular markers, leading to apparent compensation errors. Whether or not this applies to any reagents included in putative antibody panels can be determined by comparing two samples labeled with the same master mix of antibody conjugates specific for all cell surface markers to be included in each panel and submitting one of these samples to fixation/ permeabilization before acquisition on the flow cytometer. Comparison of reagent performance in the two samples rapidly indicates potential incompatibilities of individual reagents with such a procedure and, therefore, with concomitant detection of intracellular proteins. To circumvent the problem of treatment-induced down-modulation of selective surface molecules preventing their detection by the conventional cell surface labeling (eg, CD3 down-regulation on T-cell stimulation) (see Fig. 3A ), they can be labeled intracellularly with the same two-step protocol used for detection of cytokines. The antibody conjugate selected for extracellular labeling might not perform well when used for intracellular labeling, however, as it seems that not all fluorochromes are applicable in antibody conjugates used for the detection of intracellular proteins (data not shown).
Correct compensation
Any flow cytometry experiment making use of more than one color needs to include samples labeled with single antibody conjugates incorporating the relevant fluorochromes for compensation. Attention has to be paid that the positive signals in the compensation tubes are at least as bright as the brightest signal in test samples for the corresponding fluorochromes. Also, always use the same fluorochrome for compensation as used in the samples, not merely one of all possible fluorochromes for a given detector (eg, PE-Cy5, or PE-Ax647 for G660), as emission spectra and, therefore, spillover into other detectors that have to be compensated for, can differ significantly between the various fluorochromes and dyes.
Compensation controls can be prepared by labeling either cells or antibody-capture beads (CompBeads) with antibody conjugates. Ideally, anti-mIgGk-coated CompBeads should be used for antihuman antibody conjugates, as all events will be positive and signal peaks typically narrow. This is not possible when the antibody conjugate of choice is not a mIgGk clone, however, in which case cells are labeled with the reagent in question. It is mandatory to use the same antibody conjugate carrier for negative and positive controls of each respective detector, as cells have different autofluorescence properties than CompBeads (ie, unlabeled cells have to be used as the negative control for compensation samples where cells are labeled as a positive control and not CompBeads and vice versa). If this is not respected, samples will not be compensated properly (Fig. 5) .
Controls
It is of utmost importance to include all necessary controls from the beginning of a project, as not having the proper controls can markedly reduce the impact of an otherwise complete study. There are three categories of controls: (1) instrument set-up and validation, (2) gating controls, and (3) biologic controls.
Instrument validation should be performed on a daily basis and stability of the system verified before each individual experiment. This consists of adjusting instrument parameters (eg, voltages for individual detectors and optical filters) to ensure that their performance is stable over time and that measurements obtained on different days can be compared for analytic purposes. This is a prerequisite in order to validate data comparison during long-term studies. To evaluate the machine before acquiring experimental samples, the authors perform a quality control by measuring a sample of fluorescent beads that emit at known fluorescence intensities in all wavelengths measured by the photomultiplier tubes (PMTs) installed. Additionally, for every fluorochrome used in the panel, a singly labeled sample (cells or beads) needs to be acquired so that spillover fluorescence into other PMTs subsequently can be calculated by the analysis software for proper spectral compensation (discussed previously).
Even after the flow cytometer has been set up and validated and the ideal antibody panel finalized, gating controls and biologic controls are crucial to be included in each experiment. Gating controls also are referred to as fluorescence-minus-one (FMO) controls, as all antibodies are used for the labeling of FMO controls except onedtypically one that is directed against a weak antigen. Such FMO controls should be included for antigens of unknown expression and tertiary antigens (discussed previously).
Relevant biologic controls differ between research projects. For example, if cells are subjected to stimulation or other treatment before labeling and flow cytometric analysis, untreated, ''costimulation only'' controls or samples having been subjected to a control treatment are included. In a timecourse experiment, a ''time zero'' sample is required in order to determine the baseline measurement, and when studying patient samples, it usually is instructive to study corresponding samples from healthy donors.
Analysis and display of multicolor flow cytometric data
First of all, the scientific question needs to be well defined. With polychromatic flow cytometry, multifaceted results easily can be overwhelming. PE-Cy5.5 antibody. PE-Cy5.5 fluorescence was compensated using this very sample. For the left dot plot, however, unlabeled CompBeads were used as the PE-Cy5.5 neg control, whereas unlabeled PBMC were used for the right dot plot.
It is impossible, and not instructive, to look at every single subpopulation defined by every possible combination of the antibodies used. Instead, determine ahead of time what is going to be examined and use a consecutive gating strategy in order to obtain clear and interpretable data. Data always can be reanalyzed under a different perspective at a later time point if another scientific question comes up. Primary analysis should be performed using plots with a Logicle (biexponential) scale, which permits correct visualization of measurements of high and low intensities and those of negative values [10, 13] .
Traditional dot plots or variations thereof (pseudocolor plots, heat plots, zebra plots, and so forth) and Logicle plots not necessarily are the best way of representing multicolor flow cytometry results. Nevertheless, it is useful to show a single example of the gating strategy applied before presenting the digested results in a more unifying representation. There are several possible ways to collectively illustrate the findings obtained from large data sets. Fig. 6 . Gating strategy. The sequential gating strategy applied for the analysis of CD4 þ and CD8 þ T-cell responses is illustrated by the gates and arrows. Healthy donor PBMC were incubated with anti-CD3 and anti-CD28 antibodies in the presence of CD107a
Ax680 and monensin. CD3 molecules were visualized by intracellular labeling. After gating on single cells, analysis was narrowed down on small lymphocytes. Live CD3 þ T cells were identified and subdivided further into CD4 þ and CD8 þ T cells. These subsequently were analyzed for activation markers and cytokines of interest. Some pseudocolor plots for possible antigen combinations are illustrated.
There is no gold standard, because different types of representations might be better suited for one type of analysis than another.
As discussed previously, an example of the gating strategy applied for analysis of the data always should be included in a publication, even if as supplementary data available online. This is an integral part of the data presented, as it aids understanding of the final analyses and comparison with other data sets from independent publications. In the hierarchic gating strategy applied in the authors' example (Fig. 6) , singlets first were selected, defined by having a similar height (forward scatter [FSC]-H) and area (FSC-A) measurement in the FSC. Next, a gate was set around the small lymphocytes and, if a dump channel was included, cells positive for unwanted antigens gated out at this point before gating on live T cells (ViViD neg CD3 pos ). These then were divided into CD4 þ and CD8 þ subsets, and each subset was analyzed separately for activation markers and immunologic response proteins. Gates for activation and response markers need to be created separately for individual cellular lineages or subsets. As an example, gates for CD45RA expression are very different on CD4
þ and CD8 þ T cells. The publication of such a gating tree allows others to evaluate more fully the results presented and pave the way for the reproduction of the experiments in other laboratories.
Summary
Multicolor experiments can be frustratingly difficult to implement and optimize; however, it is important to spend as much time as possible trying out variations and understanding in detail the impact of every reagent (and every labeling step) on the distribution of fluorescences in the final experiment. The resulting data sets will be far more interpretable and provide a rich source of information regarding the experimental conditions. Although panel development still largely is empiric, we hope that heuristic approaches and experience soon will translate into algorithms that can be used to assist in the development of such panels.
